Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer's Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer's Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
SPC-14 shows cognitive and stress reduction benefits in preclinical models
SPC-14 在臨床前模型中顯示出認知和減壓的益處
SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license Alzheimer's disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.
佛羅里達州薩拉索塔，2024年4月10日（GLOBE NEWSWIRE）——專注於爲傳統療法和迷幻療法開發新配方和藥物遞送系統的發展階段生物製藥公司西洛製藥公司（納斯達克股票代碼：SILO）（“Silo” 或 “公司”）今天宣佈，它已行使向哥倫比亞大學許可阿爾茨海默氏病（AD）治療藥物 SPC-14 的選擇權，根據2021年訂立的贊助研究和期權協議。根據目前正在進行的許可協議條款，Silo 將獲得獨家許可，在該協議完成後，可在全球範圍內進一步開發、製造和商業化 SPC-14。該公司預計將在2024年上半年敲定並簽訂獨家許可協議。
"Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer's patients and families," said Eric Weisblum, CEO of Silo. "In our opinion, available treatments for AD remain largely inadequate. We believe that the cognitive improvement and stress reduction shown by SPC-14 in preclinical studies could hold promise for this underserved disease market."
Silo首席執行官埃裏克·韋斯布魯姆說：“哥倫比亞大學已經發現了一種可以爲阿爾茨海默氏症患者和家庭帶來緩解和希望的候選療法。”“我們認爲，可用的AD治療在很大程度上仍然不足。我們認爲，SPC-14 在臨床前研究中顯示的認知改善和壓力減輕可能爲這個服務不足的疾病市場帶來希望。”
The global Alzheimer's disease therapeutics market size is forecasted to exceed $30.8 billion by 2033, with a CAGR of 18.8% from 2024 to 20331. Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.
預計到2033年，全球阿爾茨海默氏病療法的市場規模將超過308億美元，從2024年到20331年，複合年增長率爲18.8％。在不斷擴大的老年人口中，該疾病患病率的上升以及神經學研究的進步預計將推動市場增長。
Silo believes that SPC-14 should be eligible for development under the FDA's 505(b)(2) regulatory pathway.
About SPC-14
西洛認爲，根據美國食品藥品管理局的505（b）（2）監管途徑，SPC-14 應該有資格進行開發。
關於 SPC-14
Developed by Columbia University, SPC-14 is a novel therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer's disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.
SPC-14 由哥倫比亞大學開發，是一種針對穀氨酸受體 NDMAR 和 4 型血清素受體 5HT4 的新型療法，用於治療阿爾茨海默病的認知和神經精神症狀。在最新的小動物臨床前研究中，SPC-14 可有效對抗 LH（促黃體激素）壓力，從而減輕習得的無助、堅持不懈的行爲和抑鬱症（一種衡量焦慮的標準）。